Scientist II, Drug MOA / Molecular Biology

San Diego, CA, US
Nov 21, 2018
Required Education
Position Type
Full time
Req #: 1803757
Location: San Diego, California, United States
Job Category: Research and Early Development
Work Location: 10300 Campus Point Drive 92121
Organization: Biochemistry
Employee Status: Full-time
Job Type: Regular

The key therapeutic platforms currently under investigation leverage a broad range of biological activities that allow for the development of novel paradigm-changing therapeutics. Our discovery research teams are organized into four Thematic Centers of Excellence (TCoE), including Protein Homeostasis (PH), Epigenetics, Immuno-oncology and Inflammation & Immunology. Within each these areas, discovery research, translational research, and early clinical development are integrated into a single team.


The PH TCoE is built on our legacy IMiD drugs, which exhibited therapeutic efficacy in erythema nodosum leprosum, myelodysplastic syndrome, and multiple myeloma. This class of drugs hijack the cereblon E3 ubiquitin ligase to eliminate disease-driving proteins that are otherwise considered "undruggable". The early drug discovery team in the PH TCoE is now seeking a motivated PhD scientist to assist the development of cereblon modulating agents that target novel cereblon neosubstrates for ubiquitination and degradation for the treatment of a variety of human diseases. The successful candidate will develop and utilize state-of-art biotechnology tools to identify novel substrates and perform target validation for the relevant disease indication. The successful candidate will work collaboratively in a multi-disciplinary environment, and will have the opportunity to work closely with discovery project teams and scientists across the PH TCoE functional areas and to present his or her work at project team meetings and to the senior research leadership.

Responsibilities will include, but are not limited to, the following:
  • Generate testable hypotheses, design research protocols and execute experiments
  • Lead genome-wide and focused CRISPR screens
  • Utilize CRISPR and RNAi to determine the disease relevance of novel cereblon substrates
  • Perform cellular experiments to help define the SAR of cereblon modulators
  • Utilize genetic and pharmacological approaches to define the MOA of candidate agents
  • Design and develop novel assays
  • Document, interpret and troubleshoot results
  • Convey data analysis and interpretation to supervisor and colleagues
  • Communicate with peers and supervisors and foster teamwork
  • Contribute to collaborative efforts
  • Strong commitment to quality and reproducibility
  • Demonstrate adaptability
  • Supervise or guide research staffs

Ph.D. in Molecular and Cell Biology, Biochemistry or related scientific discipline with at least 4 years of relevant work experience. Strong publication record in major scientific journals is required.

Skills/Knowledge Required:
  • Extensive wet-lab experience with routine molecular, cellular and genetic biology tools
  • Experience with CRISPR-Cas9 mediated gene editing
  • Experience with genome-wide CRISPR screens is preferred
  • Extensive training in cancer biology
  • Research experience in hematologic malignancies is preferred
  • Highly motivated and strong team player with a high degree of independence
  • Innovative and critical thinking
  • Excellent time management and organizational skills
  • Strong communication skills, both written and oral


About Us


At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

"At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients."

There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.